DCPIB|cas:82749-70-0|西域试剂

DCPIB,99.93%

产品编号：Bellancom-103371| CAS NO：82749-70-0| 分子式：C₂₂H₂₈Cl₂O₄| 分子量：427.36

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-103371	￥1100.00	杭州北京（现货）
Bellancom-103371	￥1600.00	杭州北京（现货）
Bellancom-103371	￥6500.00	杭州北京（现货）
Bellancom-103371	￥11000.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

DCPIB

产品介绍

DCPIB 是一种选择性、可逆、有效的体积调节性阴离子通道 (VRAC) 抑制剂。DCPIB 能够电压依赖性地激活钾离子通道 TREK1 和 TRAAK，抑制 TRESK，TASK1 和 TASK3 (IC₅₀ 值分别为 0.14，0.95，50.72 μM)。DCPIB 也可抑制肿胀激活的氯电流 (I_Cl,swell)，IC₅₀ 值为 4.1 μM。DCPIB 是研究 K2P 通道的结构功能的工具。

生物活性

DCPIB is a selective, reversible and potent inhibitor of volume-regulated anion channels (VRAC). DCPIB voltage-dependently activates potassium channels TREK1 and TRAAK, and inhibits TRESK, TASK1 and TASK3 (IC₅₀s: 0.14, 0.95, 50.72 μM, respectively). DCPIB is also a selective blocker of swelling-induced chloride current (I_Cl,swell), with an IC₅₀ of 4.1 μM. DCPIB is a useful tool for investigating structure-function studies of K2P channels.

体外研究

DCPIB (10 μM) activates TREK1 and enhances TRAAK currents in COS-7 cells.
DCPIB (10 μM) prominently and reversibly suppresses TRESK currents in COS-7 cells, with an IC₅₀ of 0.14 μM.
DCPIB (10 μM) displays selectivity for I_Cl,swell and has no significant inhibitory effects on I_Cl,Ca in CPAE cells.
DCPIB (10 μM, 5 min) has no effect on attenuate subsequent swelling in cardiomyocytes.
DCPIB (10 μM, 3 h) inhibits LPS-induced MAPK activation in BV2 cells.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Immunofluorescence

Cell Line:	BV2 cells
Concentration:	10 μM
Incubation Time:	3 h
Result:	Significantly decreased Ki67 positive staining microglia and pro-inflammatory cytokine (TNF-α, IL-1β) secretion.

Western Blot Analysis

Cell Line:	BV2 cells
Concentration:	10 μM
Incubation Time:	3 h
Result:	Inhibited migratory potential of transient OGD (Oxygen-glucose deprivation) exposed BV2 cells.

体内研究
(In Vivo)

LDN-212854 (intracerebroventricular infusion, 1 mM, 10 μL) suppresses microglial activation and ameliorates neuronal damage in rMCAO rats.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Reversible middle cerebral artery occlusion (rMCAO) model
Dosage:	1 mM, 10 μL
Administration:	Administered manually for 20s by intracerebroventricular infusion
Result:	Diminished Pyramidal neurons injury induced by rMCAO in the CA1 region.

体内研究

LDN-212854 (intracerebroventricular infusion, 1 mM, 10 μL) suppresses microglial activation and ameliorates neuronal damage in rMCAO rats.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Reversible middle cerebral artery occlusion (rMCAO) model
Dosage:	1 mM, 10 μL
Administration:	Administered manually for 20s by intracerebroventricular infusion
Result:	Diminished Pyramidal neurons injury induced by rMCAO in the CA1 region.

体内研究

LDN-212854 (intracerebroventricular infusion, 1 mM, 10 μL) suppresses microglial activation and ameliorates neuronal damage in rMCAO rats.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Reversible middle cerebral artery occlusion (rMCAO) model
Dosage:	1 mM, 10 μL
Administration:	Administered manually for 20s by intracerebroventricular infusion
Result:	Diminished Pyramidal neurons injury induced by rMCAO in the CA1 region.

性状

Solid

溶解性数据

In Vitro:

DMSO : 100 mg/mL (233.99 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.3399 mL	11.6997 mL	23.3995 mL
5 mM	0.4680 mL	2.3399 mL	4.6799 mL
10 mM	0.2340 mL	1.1700 mL	2.3399 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.08 mg/mL (4.87 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (4.87 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: 2.08 mg/mL (4.87 mM); Clear solution; Need ultrasonic

此方案可获得 2.08 mg/mL (4.87 mM) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
3.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.08 mg/mL (4.87 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (4.87 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。